COMBINED DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled:

2- (ARYLALKOXY) -1-PHENYLETHYLAMINE DERIVATIVES AS NK1 ANTAGONIST AND SEROTONIN REUPTAKE INHIBITORS

the spec	cification of which:					
	is attached hereto.		·			
OR	was filed on	with Express Mail No.	(Application Number not yet known).			
OR						
	was filed on 6 April 20	6 April 2005 as United States Application Number or Application Number PCT/SE2005/000499 and was amended on				
	PCT International Application	on Number PC1/SE2003/000499 (if applicable).	and was amended on			
		(II applicable).				
	I hereby state that I have rev	viewed and understand the contents of	the above-identified specification,			
includir	ng the claims, as amended by	any amendment referred to above.				
		· 1 · · · · · · · · · · · · · · · · · ·	a a stantability on defined in 27 CED			
C1 50	I acknowledge the duty to di	isclose information which is material t	o patentability as defined in 37 CFR			
§1.56.						
			O/			
1.	•	nder Title 35, United States Code, §11	9(e)(1) of any United States provisional			
applica	tion(s) listed below:					
	U.S. Serial No.	Filing Date	Status			
	I hereby claim the benefit ur	nder Title 35. United States Code, §12	0 of any United States application(s), or			
§365(c) of any PCT International application designating the United States, listed below and, insofar as the subject						
matter	of each of the claims of this ar	pplication is not disclosed in the prior	United States application or PCT			
Internat	tional application in the manne	er provided by the first paragraph of T	itle 35, United States Code, §112, I			
acknow	rledge the duty to disclose all	information I know to be material to p	atentability as defined in Title 37, Code			
		ch became available between the filing	g date of the prior application and the			
nationa	l or PCT international filing d	late of this application:				
	U.S. Serial No.	Filing Date	Status			
	- CIOT DULLING					

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
Sweden	0400968-4	14 April 2004	⊠Yes □No
			Yes No

I hereby appoint all registered practitioners associated with **Customer Number 22466** to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to:

Customer Number 22466

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor:

Cathy DANTZMAN

Inventor's Signature:

Residence Address:

Wilmington, Delaware

Citizenship:

US

Post Office Address:

AstraZeneca Pharmaceuticals, P.O. Box 15437, Wilmington, Delaware 19850-5437, USA